Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors
Open Access
- 1 July 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pancreas
- Vol. 47 (6), 759-771
- https://doi.org/10.1097/mpa.0000000000001063
Abstract
Two issues were put forth by clinicians in the management of the advanced stages of rare variants of pancreatic ductal adenocarcinoma and other exocrine histotypes with peculiar clinical and pathological features: Do chemotherapy regimens recommended in pancreatic ductal adenocarcinoma patients have a clinical activity in rare pancreatic tumors? Or should other chemotherapy combinations be considered in this subset of patients? We conducted a multicenter retrospective study that collected data from 2005 to 2016 at 14 Italian cancer centers with the aim to evaluate tumor response and time to progression for first- and second-line and overall survival. Of approximately 4300 exocrine pancreatic cancer patients, 79 advanced cases affected by rare histological types were identified, with pancreatic acinar cell cancer (n = 23), pancreatic adenosquamous cancer (n = 16), and mucinous cystic neoplasm with an associated invasive mucinous cystadenocarcinoma (n = 15) most represented. Survival analyses for each subgroup in relation with the different chemotherapy regimens showed the lack of statistical significance correlations. Because of the lack of clinical trials in patients affected by these rare pancreatic histotypes, only their molecular classification would help clinicians in future therapeutic choice.This publication has 80 references indexed in Scilit:
- Successful Salvage Chemotherapy with FOLFIRINOX for Recurrent Mixed Acinar Cell Carcinoma and Ductal Adenocarcinoma of the Pancreas in an Adolescent PatientCase Reports in Oncology, 2013
- 415 Patients with Adenosquamous Carcinoma of the Pancreas: A Population-Based Analysis of Prognosis and SurvivalJournal of Surgical Research, 2012
- Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five monthsPancreatology, 2012
- Acinar Cell Carcinoma of the Pancreas: New Genetic and Treatment Insights into a Rare MalignancyThe Oncologist, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Pancreatic Panniculitis Associated with Acinar Cell Carcinoma of the Pancreas: A Case ReportAnnals of Dermatology, 2011
- Rare tumors in the pancreatic regionNorth American Journal of Medical Sciences, 2011
- Complete response of anaplastic pancreatic carcinoma to paclitaxel treatment selected by chemosensitivity testingInternational Journal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Clear Cell Carcinoma of the Pancreas -A Case Report and Review of the Literature-Cancer Research and Treatment, 2009